Table of Contents
What changed
Reported revenue rose 4.1% to $182.0m, with management pointing to 10.1% growth against normalised FY23 revenue of $165.3m after stripping out the one-off Coretex acquisition-accounting adjustment. EBITDA grew 17.9% to $53.3m, but operating profit halved to $0.8m and the loss before tax widened to $7.0m from $5.1m. NPAT improved to a $0.3m loss from a $3.0m loss, driven almost entirely by a $6.7m tax benefit rather than operating performance.
The more significant shift is in cash and the balance sheet. Operating cash flow more than doubled to $52.9m (from $24.1m), free cash flow to the firm swung to +$1.3m from -$29.9m, and gross borrowings fell to $36.6m from $70.6m. Net debt dropped to $22.1m from $62.5m, cutting net debt/EBITDA from 1.4x to 0.4x. New Zealand remains the profit engine (EBITDA margin ~67.6%), North America ran at ~27.5%, and Corporate & Development losses widened to -$33.6m.
What matters
- Cash conversion inflection. OCF/EBITDA jumped from 53.3% to 99.3%, and FCF turned positive despite capex rising to $32.2m (17.7% of revenue, up from 15.7%). This is the single most important datapoint in the release because it converts the FY23 deleveraging question into a funded reality.
- Headline earnings are tax-flattered. PBT deteriorated by $1.9m but NPAT "improved" by $2.7m purely because of a $6.7m tax benefit (effective tax rate 95.7% vs 41.2%). The cleaner read is that underlying operating profitability went backwards at the same time revenue grew.
- Leverage is no longer a constraint. With net debt at $22.1m against $53.3m EBITDA, EROAD has materially more flexibility than a year ago. Equity rose $54.2m to $303.0m while liabilities fell $23.5m.
Expectations
No quantified FY25 guidance or forward-work metric was disclosed. H1 FY24 was 48.8% of full-year revenue and 48.0% of EBITDA, implying only a modest second-half skew — the shape is close to balanced rather than strongly back-loaded. That limits how much FY25 can be inferred from intra-year cadence alone. Against the prior-year "strategic discipline" framing, the result delivers on the cash/leverage narrative but does not yet evidence a clean break into sustained statutory profitability on continuing operations reporting.
Quality of result
The cash and leverage improvement looks genuine: EBITDA rose in absolute dollars, OCF/EBITDA normalised to ~99%, and borrowings were physically repaid rather than refinanced. However, several quality caveats weigh against the headline:
- The near-breakeven NPAT is tax-assisted; PBT actually worsened.
- Receivable days extended to 50.7 from 47.0, a ~$2.8m build in trade debtors that partially flatters revenue growth relative to collections.
- "Normalised" revenue growth of 10.1% rests on stripping a Coretex acquisition-accounting adjustment; no full non-GAAP reconciliation is visible in the supplied excerpts.
- Operating profit of $0.8m is a thin cushion against any depreciation or amortisation step-up from the $32.2m capex program.
Unresolved
- What is the post-tax result from continuing operations on a like-for-like basis, and how does it reconcile to the $3.2m continuing-operations figure management cites versus the $0.3m total NPAT?
- Is the FY24 tax benefit a recurring feature (deferred tax recognition) or a one-off that reverses in FY25?
- With capex still running at ~18% of revenue, how much of the FY24 FCF swing is structural versus a one-year lull in working-capital build?
- No FY25 revenue, EBITDA or unit growth target was provided; no customer concentration disclosure was made.
This briefing cannot assess unit economics, churn, ARPU trends, or the competitive position of the North American business from the supplied materials.
Key metrics
| Metric | FY24 | FY23 | Change |
|---|---|---|---|
| Revenue | $0.2m | $0.2m | +4.1% ↑ |
| EBITDA | $0.1m | $0.0m | +17.9% ↑ |
| Net profit after tax | −$0.0m | −$0.0m | +90.0% ↑ |
| Net cash inflow from operating activities | $0.1m | $0.0m | +119.5% ↑ |
| Operating profit | $0.0m | $0.0m | -52.9% ↓ |
| Profit before tax | −$0.0m | −$0.0m | -37.3% ↓ |
| Cash and cash equivalents | $0.0m | $0.0m | +79.0% ↑ |
| Total assets | $0.4m | $0.4m | +7.6% ↑ |
Reference: annolyse.ai/briefings/erd-fy24
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Corporate & Development | $75m | $62.3m | −$33.6m | +1.8pp |
| North America | $80m | $72.6m | $22m | -0.8pp |
| New Zealand | $92m | $83.7m | $62.2m | -1.0pp |
| Australia | $10.7m | $9.3m | $3m | +0.0pp |
Reference: annolyse.ai/briefings/erd-fy24
Analytical metrics
| Metric | FY24 | FY23 | Context |
|---|---|---|---|
| OCF / EBITDA (cash conversion) | 99.3% | 53.3% | stable |
| FCF pre-lease | $1.3m | −$29.9m | +$31.2m |
| FCF / NPAT | 433.3% | 996.7% | complementary conversion metric |
| Capex % revenue | 17.7% | 15.7% | — |
| Capex | −$0.0m | −$0.0m | −$0.0m |
| Free cash flow | $0.0m | −$0.0m | +$0.0m |
| Debtor days | 50.7 | 47.0 | +3.7 days |
| Trade debtors | $0.0m | $0.0m | +$0.0m |
| Net debt | $22.1m | $62.5m | −$40.4m |
| Net debt / EBITDA | 0.40x | 1.40x | Strengthening |
| Gross borrowings | $0.0m | $0.1m | −$0.0m |
| ROE (annualised) | -0.1% | -1.2% | Strengthening |
| HY24 share of FY24 revenue | 48.8% | — | Other half was 51.2% |
| HY24 share of FY24 EBITDA | 48.0% | — | Other half was 52.0% |
| Profit from continuing operations | — | −$0.0m | — |
Reference: annolyse.ai/briefings/erd-fy24
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.